



**Yuliya Semenova, MD, candidate of  
medical sciences**

**Assistant Professor,  
Nazarbayev University School of Medicine**

*Evidence-based practice and policy to improve antibiotic  
stewardship and reduce antimicrobial resistance in Central Asia  
(CRP 2024-2026)*

PI: Yuliya Semenova, NUSOM  
Co-PI: Lisa Lim, GSPP NU  
Co-PI: Larissa Makalkina, Astana Medical University



# Antibiotic consumption at the community level in Kazakhstan



# Study materials

- Data on antibiotic sales by pharmacies in Kazakhstan and antibiotics distributed through the free prescription program of primary healthcare facilities from **2019 to 2023**.
- The data was procured from **Vi-ORTIS** Consulting Company, which collects data on the procurement and sales of medicines by pharmacies in Kazakhstan.
- The data on systemic antibacterials (**J01** code) was downloaded from Vi-ORTIS web portal.

# Study methods


- Data disaggregation at the ATC5 level was applied to upload information for each systemic antibacterial sold into the **GLASS** (Global Antimicrobial Resistance and Use Surveillance System).
- Defined Daily Doses (**DDD**) per 1000 inhabitants were used to estimate the proportion of the population receiving each type of antibiotic on a given day.
- Based on the DDD per 1000 inhabitants, all antibiotics were classified according to **AWaRe** categories: **Access, Watch, and Reserve**.
- SPSS version 26.0 was used for statistical analysis.




# Consumption of antibiotics by AWaRe categories

Defined Daily Dose per 1000 inhabitants	2019	2020	2021	2022	2023	Average change annum; p-level
<b>Total DDD per 1000 inhabitants</b>	8.81	9.27	8.54	8.44	8.17	-2.42%; p=0.049
<b>«Access» group</b>	4.95	4.31	3.93	3.91	3.92	-5.48%; p=0.029
<b>Percentage (%) of the total DDD</b>	<b>57.01</b>	<b>47.09</b>	<b>46.57</b>	<b>46.81</b>	<b>48.34</b>	<b>-3.30%</b> ; p=0.132
<b>«Watch» group</b>	3.73	4.85	4.51	4.44	4.19	1.45%; p=0.353
<b>Percentage (%) of the total DDD</b>	<b>42.98</b>	<b>52.90</b>	<b>53.43</b>	<b>53.19</b>	<b>51.66</b>	<b>3.80%</b> ; p=0,154
<b>«Reserve» group</b>	0.00042	0.00035	0.00029	0.0001	0.000002	-69.72%; p=0.036
<b>Percentage (%) of the total DDD</b>	<b>0.00492</b>	<b>0.00388</b>	<b>0.00346</b>	<b>0.00121</b>	<b>0.00002</b>	<b>-70.41%</b> ; p=0.039

# The champions of consumption, determined by DDD per 1000 inhabitants




# Top 7 antibiotics, determined by DDD per 1000 inhabitants




# Prognostic modelling of antibiotic consumption

**Access**



2024	2025	2026	2027	2028
49.2	49.2	49.2	49.2	49.2

**Watch**



2024	2025	2026	2027	2028
50.8	50.8	50.8	50.8	50.8



# Recommendations

- Creating and putting into action a national antibacterial drug formulary that restricts certain antibiotics' usage to specific indications or scenarios where there are no alternatives.
- Promoting awareness among both the public and healthcare professionals regarding the risks associated with AMR and the crucial role of antibiotic stewardship.
- Implementing antibiotic stewardship programs in primary care settings to aid physicians in prescribing appropriately. This involves incorporating updated clinical protocols, employing delayed antibiotic prescribing strategies, and providing patient education materials.

# Recommendations

- Enhancing the accessibility of rapid diagnostic tests at the primary healthcare level, enabling the differentiation between bacterial and viral infections, is paramount.
- Enforcing mandatory prescriptions for all antibiotics and closely monitoring their sale and distribution.
- Identifying healthcare professionals as "champions" for the rational use of antibiotics, individuals capable of assuming leadership roles within their professional spheres.
- Promoting vaccination will help prevent infections that require antibiotic treatment.



Thank you for attention!

